262 related articles for article (PubMed ID: 32640313)
1. Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation.
Fang J; Su Y; Zavras PD; Raval AD; Tang Y; Perales MA; Giralt S; Stern A; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1937-1947. PubMed ID: 32640313
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes.
Huang YT; Su Y; Kim SJ; Nichols P; Burack D; Maloy M; Giralt S; Perales MA; Jakubowski AA; Papanicolaou GA
Biol Blood Marrow Transplant; 2019 Apr; 25(4):791-799. PubMed ID: 30476551
[TBL] [Abstract][Full Text] [Related]
3. Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation.
Tan CA; Palen L; Su Y; Li Y; Gennarelli RL; Perales MA; Cohen N; Papanicolaou GA; Shah GL; Seo SK
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38838781
[TBL] [Abstract][Full Text] [Related]
4. Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34
Huang YT; Kim SJ; Lee YJ; Burack D; Nichols P; Maloy M; Perales MA; Giralt SA; Jakubowski AA; Papanicolaou GA
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1759-1766. PubMed ID: 28668490
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Refractory Cytomegalovirus Infection in the First Year after Allogeneic Hematopoietic Cell Transplantation.
Karantoni E; Zavras PD; Su Y; Fang J; Tamari R; Cho C; Perales MA; Stern A; Papanicolaou GA
Transplant Cell Ther; 2022 Jul; 28(7):403.e1-403.e7. PubMed ID: 35476955
[TBL] [Abstract][Full Text] [Related]
6. Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study.
Zavras P; Su Y; Fang J; Stern A; Gupta N; Tang Y; Raval A; Giralt S; Perales MA; Jakubowski AA; Papanicolaou GA
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1482-1491. PubMed ID: 32315708
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation.
Cheng WY; Avery RK; Thompson-Leduc P; Cheung HC; Bo T; Duh MS; Hirji I
J Med Econ; 2022; 25(1):367-380. PubMed ID: 35240904
[TBL] [Abstract][Full Text] [Related]
8. Cytomegalovirus infection and associated hospitalization and costs among individuals undergoing allogeneic hematopoietic stem cell transplant.
Schelfhout J; Brown H; House JA; Raval AD
Curr Med Res Opin; 2020 Jan; 36(1):43-50. PubMed ID: 31490097
[No Abstract] [Full Text] [Related]
9. Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients.
El Haddad L; Ghantoji SS; Park AK; Batista MV; Schelfhout J; Hachem J; Lobo Y; Jiang Y; Rondon G; Champlin R; Chemaly RF
J Med Virol; 2020 Jan; 92(1):86-95. PubMed ID: 31448830
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy.
Saullo JL; Li Y; Messina JA; Thompson J; Dalton T; Giri VK; Reed SD; Miller R; Horwitz ME; Alexander BD; Sung AD
Biol Blood Marrow Transplant; 2020 Mar; 26(3):568-580. PubMed ID: 31712193
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic impact of treated CMV infection in adult CMV-seropositive patients after allogeneic hematopoietic cell transplantation.
Peffault De Latour R; Chevallier P; Blaise D; Alami S; Lévy-Bachelot L; Allavoine T; Tadmouri A; Blomkvist J; Duhamel A; Srour M; Beauvais D; Yakoub-Agha I
J Med Virol; 2020 Dec; 92(12):3665-3673. PubMed ID: 32297984
[TBL] [Abstract][Full Text] [Related]
12. Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients.
Camargo JF; Kimble E; Rosa R; Shimose LA; Bueno MX; Jeyakumar N; Morris MI; Abbo LM; Simkins J; Alencar MC; Benjamin C; Wieder E; Jimenez A; Beitinjaneh A; Goodman M; Byrnes JJ; Lekakis LJ; Pereira D; Komanduri KV
Biol Blood Marrow Transplant; 2018 Apr; 24(4):806-814. PubMed ID: 29217388
[TBL] [Abstract][Full Text] [Related]
13. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation.
Webb BJ; Harrington R; Schwartz J; Kammerer J; Spalding J; Lee E; Dodds B; Kaufusi S; Goodman BE; Firth SD; Martin G; Sorensen J; Hoda D
Transpl Infect Dis; 2018 Oct; 20(5):e12961. PubMed ID: 29975816
[TBL] [Abstract][Full Text] [Related]
14. The clinical and economic burden of cytomegalovirus management post allogeneic hematopoietic stem cell transplantation in Japan - a retrospective database study.
Ueno R; Nishimura S; Fujimoto G; Piao Y; Takenaka K
Curr Med Res Opin; 2019 Dec; 35(12):2089-2096. PubMed ID: 31353971
[No Abstract] [Full Text] [Related]
15. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
[TBL] [Abstract][Full Text] [Related]
16. Use of maintenance therapy and incidence of recurrent Cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients.
Camargo JF; Anderson AD; Rosa R; Kimble E; Komanduri KV; Morris MI
Transpl Infect Dis; 2019 Apr; 21(2):e13054. PubMed ID: 30689300
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Preemptive Therapy Versus Prophylaxis in a Randomized Clinical Trial for the Prevention of Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors.
Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Limaye AP
Clin Infect Dis; 2021 Nov; 73(9):e2739-e2745. PubMed ID: 32712663
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.
Marty FM; Winston DJ; Chemaly RF; Mullane KM; Shore TB; Papanicolaou GA; Chittick G; Brundage TM; Wilson C; Morrison ME; Foster SA; Nichols WG; Boeckh MJ;
Biol Blood Marrow Transplant; 2019 Feb; 25(2):369-381. PubMed ID: 30292744
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus resistance in CD34
Kim SJ; Huang YT; Foldi J; Lee YJ; Maloy M; Giralt SA; Jakubowski AA; Papanicolaou GA
Transpl Infect Dis; 2018 Jun; 20(3):e12881. PubMed ID: 29570237
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation.
Hill JA; Moon SH; Chandak A; Zhang Z; Boeckh M; Maziarz RT
Transplant Cell Ther; 2022 Sep; 28(9):619.e1-619.e8. PubMed ID: 35764288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]